Press releases

Release issued 17th January 2007

Innocoll Annunces Expansion of the Distribution Partnership for its CollaRx® GENTAMICIN SURGICAL IMPLANT with BurnsAdler to Include Brazil and Dominican Republic and a Separate Promotional Agreement between BurnsAdler and Serral for the same Product in Mexico.

Ashburn , Va. , January 1 7 /PRNewswire/— Innocoll, Inc. announces that its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has expanded the distribution partnership for its CollaRx® GENTAMICIN SURGICAL IMPLANT with BurnsAdler Pharmaceuticals, Inc. to include Brazil and Dominican Republic. Additionally, BurnsAdler has recently established a long term licensing, promotion and distribution agreement with Serral, S.A de C.V (‘Serral’) to market the same product (branded Garacoll®) in Mexico. Serral, whose headquarters are located in Mexico City, is a local pharmaceutical company which has marketed pharmaceutical products since 1948 and will compliment BurnsAdler’s direct marketing activities in the territory.

GENTAMICIN SURGICAL IMPLANT was developed using Innocoll’s proprietary collagen-based drug delivery technology (CollaRx®). It is approved in over 50 countries worldwide and is marketed under a variety of other trade names (Collatamp® G, Collatamp® EG, Sulmycin® Implant, Garamycin® Schwamm, Duracol®, Duracoll®, Gentacol®, Gentacoll®, Garacol® and Cronocol®) in Europe, Middle East, Africa and Asia. Innocoll, Inc. acquired the product rights from Essex Chemis AG, an affiliated company of Schering-Plough Corporation (NYSE: SGP) in 2005 and has since assumed all sales, marketing and distribution activities for the product through Innocoll Pharmaceuticals Ltd. BurnsAdler licensed the product for sale in Mexico, Chile, Colombia, Argentina, and select Caribbean islands from Innocoll Pharmaceuticals in August 2006.

The product is approved as a drug in Central and South America and is indicated for the treatment and prevention of post-operative acquired infection. Used in combination with standard systemic antibiotic therapy, the product delivers high concentrations of gentamicin locally, with minimal systemic concentrations. It can be used in a wide range of surgery types including orthopedic, cardiac, abdominal, vascular, and general surgery.

Dr. Michael Myers, President and CEO of Innocoll Inc., stated, “We are delighted to expand our partnership with BurnsAdler to include Brazil And Dominican Republic. Brazil is one of the top 10 pharmaceutical markets estimated at $8.5 billion and together with Mexico is a key territory in the region. We are also gratified that BurnsAdler is actively pursuing additional promotional agreements with local pharmaceutical companies in other Latin American countries. Mexico is already an important market for the product and we are confident that BurnsAdler together with Serral can build upon the strong sales achieved in the territory to date.”

About GENTAMICIN SURGICAL IMPLANT
GENTAMICIN SURGICAL IMPLANT is a biodegradable fully resorbable implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin, and is indicated as an adjunct to systemic antibiotic therapy for the treatment and prevention of post-surgical acquired infection in both hard and soft tissues. It is based on Innocoll's CollaRx® technology, a proprietary collagen-based system which locally delivers a wide variety of drug products, and can be formulated for implantable or topical application as a lyophilized sponge or as a cast film.

About Innocoll, Inc.
Innocoll is a privately held, fully integrated, global, hospital specialty pharmaceutical company specializing in surgical and dermatological products. It develops and markets internationally a range of medical products using its proprietary collagen-based technologies, CollaRx® and LiquiColl®. For more information, please visit http://www.innocoll.com . For product or pipeline information, please visit http://www.innocoll-pharma.com .

About BurnsAdler Pharmaceuticals, Inc.
BurnsAdler Pharmaceuticals, Inc. is a specialty pharmaceutical company that promotes, sells and distributes products in South America, Mexico, Canada, Puerto Rico and the Caribbean. BurnsAdler’s portfolio strategy focuses on pharmaceutical products and medical devices used in oncology, gastroenterology, cardiovascular medicine, orthopedic medicine, hospitals and other critical care settings.

Contact: Martha Clancy
Corporate Communications Officer
+353 (0) 906 634902
mclancy@innocoll-tech.com

(3rd April 2012) Innocoll Provides Update of Regulatory and Partnering Activities for CollaGUARD® Adhesion Barrier and Launches New Product Website

(17th February 2012) Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl® and Agreement of the Phase 3 Program

(1st February 2012) Innocoll Enters CollaGUARD® Distribution Partnership with Flynn Pharma Ltd in the UK and Inresa Arzneimittel GmbH in Germany

(15th November 2011) Innocoll Enters Partnership with Merus Labs in Canada for the Distribution of CollaGUARD

(19th October 2011) Innocoll Enters Partnership with Pioneer Pharma in China for the Distribution of CollaGUARD